↓ Skip to main content

Cochrane Database of Systematic Reviews

Thrombolytic therapy for pulmonary embolism

Overview of attention for article published in this source, July 2009
Altmetric Badge

Mentioned by

4 tweeters
1 Wikipedia page


61 Dimensions

Readers on

77 Mendeley
Thrombolytic therapy for pulmonary embolism
Published by
John Wiley & Sons, Ltd, July 2009
DOI 10.1002/14651858.cd004437.pub3
Pubmed ID

Dong, Bi Rong, Hao, Qiukui, Yue, Jirong, Wu, Taixiang, Liu, Guan Jian


Thrombolytic therapy is usually reserved for patients with clinically serious or massive pulmonary embolism (PE). Evidence suggests that thrombolytic agents may dissolve blood clots more rapidly than heparin and might reduce the death rate associated with PE. However, there are still concerns about the possible risk of adverse effects of thrombolytic therapy, such as major or minor haemorrhages. This is an update of a Cochrane review first published in 2006.

Twitter Demographics

The data shown below were collected from the profiles of 4 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 77 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
United Kingdom 3 4%
United States 1 1%
Singapore 1 1%
Brazil 1 1%
Unknown 71 92%

Demographic breakdown

Readers by professional status Count As %
Student > Postgraduate 17 22%
Other 14 18%
Researcher 11 14%
Professor > Associate Professor 6 8%
Student > Bachelor 5 6%
Other 15 19%
Unknown 9 12%
Readers by discipline Count As %
Medicine and Dentistry 57 74%
Agricultural and Biological Sciences 3 4%
Nursing and Health Professions 1 1%
Arts and Humanities 1 1%
Psychology 1 1%
Other 1 1%
Unknown 13 17%